
Cadence Pharmaceuticals was a San Diego-based specialty pharmaceutical company focused on developing and commercializing products for use in the hospital setting, primarily targeting acute pain management. The company's lead product was Ofirmev (IV acetaminophen). Cadence raised approximately $197 million in funding before being acquired by Mallinckrodt PLC in 2014 for approximately $1.3 billion.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account